Clinical trials: Psychotic Symptoms
Alzheimer's Disease, Psychosis
Treatment of Behavioral Symptoms in Alzheimer's Disease
The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT00009217
- Testing
- Haloperidol-Haloperidol
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- RAPSODI (NCT03043820)
- Testing
- Raloxifene
- Where
- Netherlands
- Volunteers
- 110 people
- Sponsor
- Iris Sommer
Bipolar I Disorder, Mania
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or…
- Trial name
- NCT07288320
- Testing
- NBI-1117568
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Primary Health Care, Mental Disorder
The Effects of Primary Care Behavioral Health in Primary Care in Sweden
The novel multi-professional service delivery model "Primary Care Behavioural Health" (PCBH) has been suggested as an effective way to integrate behavioural health services into routine primary care to overcome the growing…
- Conditions
- Primary Health Care, Mental Disorder, Behavioral Symptoms
- Trial name
- NCT05633940
- Testing
- Implementation of the service delivery model primary care behavioral health
- Where
- Sweden
- Volunteers
- 500 people
- Sponsor
- Region Östergötland
Schizophrenia, Major Depressive Disorder
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures.
- Conditions
- Schizophrenia, Major Depressive Disorder, Anxiety Disorders
- Trial name
- NCT03790085
- Testing
- Risperidone, Olanzapine, Aripiprazole
- Where
- China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University General Hospital
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235585
- Testing
- bitopertin [RO4917838]
- Where
- 120 sites in United States, Brazil and 12 more
- Volunteers
- 597 people
- Sponsor
- Hoffmann-La Roche
Delirium, Critical Illness
Haloperidol for Delirium in Adult Critically Ill Patients
The EuRIDICE trial will study whether haloperidol as a first line treatment for ICU delirium reduces delirium duration (and severity).
- Conditions
- Delirium, Critical Illness, Intensive Care Psychosis, Cognitive Impairment
- Trial name
- EuRIDICE (NCT03628391)
- Testing
- Haloperidol
- Where
- 8 sites in Netherlands
- Volunteers
- 142 people
- Sponsor
- Erasmus Medical Center
Chronic Mental Illness, Major Depression
My Coach Connect: An Automated Telephone-based Reporting System for Patients With Mental Illness
This is a pilot study for a novel, automated telephone system called "My Coach Connect". The purpose of the study is to evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in…
- Conditions
- Chronic Mental Illness, Major Depression, Schizophrenia, Bipolar Disorder
- Trial name
- MCC (NCT01749124)
- Testing
- My Coach Connect
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- RAND
Schizophrenia and Related Disorders, Schizophrenia
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
Psychomotor slowing is a major problem in psychosis. Aberrant function of the cerebral motor system is linked to psychomotor slowing in patients, particularly resting state hyperactivity in premotor cortices.
- Conditions
- Schizophrenia and Related Disorders, Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder
- Trial name
- OCoPS-P (NCT03921450)
- Testing
- 1 Hz rTMS, iTBS
- Where
- Switzerland
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- University of Bern
Pain, Schizophrenia
Pain and Schizophrenia
The aim of the investigators project is to explore the mechanisms of pain insensitivity in patients with schizophrenia, in order to prevent its invalidating consequences.
- Trial name
- NCT01244542
- Testing
- unpleasant stimuli
- Where
- 5 sites in France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Delusions, Depression
Effect of 4-session Metacognitive Training in Chinese Adult Outpatients With Schizophrenia Spectrum Disorders and Major Depressive Disorder
Psychological studies have shown that individuals tend to attribute causes of positive and negative events differently. Specifically, individuals hold an internalising or externalising bias of attribution which, in the case of…
- Trial name
- NCT03449394
- Testing
- Metacognitive Training
- Where
- Hong Kong
- Volunteers
- 113 people
- Sponsor
- Chinese University of Hong Kong
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Auditory Hallucinations, Schizophrenia
Neuro-VR: Augmenting a Virtual Reality-based Therapy With Biofeedback for Auditory Hallucinations
The primary goal of this pilot study is to examine the feasibility and acceptability of augmenting a Virtual Reality-based intervention for treating auditory hallucinations in schizophrenia with electroencephalogram (EEG)-based…
- Trial name
- Neuro-VR (NCT06628323)
- Testing
- Virtual Reality-based Intervention employing Neurofeedback, Virtual Reality-based Intervention
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Obesity, Weight Loss
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
The aim of this study is to collect pilot data to compare the effectiveness of treatment with Alpha Lipoic Acid (ALA) for reduction in body weight in 40 obese outpatients with schizophrenia or schizoaffective disorder in an…
- Conditions
- Obesity, Weight Loss, Schizophrenia
- Trial name
- ALA (NCT01355952)
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Self Harm, First Episode Psychosis
Psychosocial Intervention for Suicidal Ideation in Individuals With FEP: A Feasibility Trial
To check the feasibility and acceptability of Culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and Culturally Adapted Manual Assisted Brief Psychological Intervention for Self-harm (CMAP), which we have…
- Trial name
- CMAP-FEP (NCT05728138)
- Testing
- CMAP Plus CBT
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)
This is an extension study to further test the efficacy and safety of asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of schizophrenia.
- Trial name
- NCT00265343
- Testing
- asenapine, olanzapine
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Psychotic Disorder
Delusion Ideation in the Context of Everyday Life
The project aims to investigate the feasibility and acceptability of a blended face-to-face and smartphone intervention for distressing thoughts and experiences in people with schizophrenia spectrum disorders.
- Trial name
- DICE (NCT06207526)
- Testing
- Blended face-to-face and smartphone intervention
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Charite University, Berlin, Germany
Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
- Trial name
- NCT01467089
- Testing
- Two way video assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Schizophrenia
The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia
The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.
- Trial name
- NCT00148447
- Testing
- escitalopram
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- BeerYaakov Mental Health Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.